Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorKroese, Tiuri E.
dc.contributor.authorvan Hillegersberg, Richard
dc.contributor.authorSchoppmann, Sebastian F.
dc.contributor.authorDeseyne, Pieter
dc.contributor.authorNafteux, Philippe
dc.contributor.authorObermannova, Radka
dc.contributor.authorAlsina Maqueda, Maria
dc.date.accessioned2022-09-05T11:55:36Z
dc.date.available2022-09-05T11:55:36Z
dc.date.issued2022-03
dc.identifier.citationKroese TE, van Hillegersberg R, Schoppmann S, Deseyne PRAJ, Nafteux P, Obermannova R, et al. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. Eur J Cancer. 2022 Mar;164:18–29.
dc.identifier.issn0959-8049
dc.identifier.urihttp://hdl.handle.net/11351/8028
dc.descriptionOesophageal neoplasm; Oligometastasis; Radiosurgery
dc.description.abstractBackground Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (<50%), fair (50%–75%), or consensus (≥75%). Results A total of 47 MDTs across 16 countries fully discussed the cases (96%). Oligometastatic disease was considered in patients with 1–2 metastases in either the liver, lung, retroperitoneal lymph nodes, adrenal gland, soft tissue or bone (consensus). At follow-up, oligometastatic disease was considered after a median of 18 weeks of systemic therapy when no progression or progression in size only of the oligometastatic lesion(s) was seen (consensus). If at restaging after a median of 18 weeks of systemic therapy the number of lesions progressed, this was not considered as oligometastatic disease (fair agreement). There was no consensus on treatment strategies for oligometastatic disease. Conclusion A broad consensus on definitions of oligometastatic oesophagogastric cancer was found among MDTs of oesophagogastric cancer expert centres in Europe. However, high practice variability in treatment strategies exists.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesEuropean Journal of Cancer;164
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectMetàstasi
dc.subjectAparell digestiu - Càncer - Cirurgia
dc.subjectMastectomia
dc.subject.meshMetastasectomy
dc.subject.meshStomach Neoplasms
dc.subject.meshNeoplasm Metastasis
dc.titleDefinitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ejca.2021.11.032
dc.subject.decsmetastasectomía
dc.subject.decsneoplasias gástricas
dc.subject.decsmetástasis neoplásica
dc.relation.publishversionhttps://doi.org/10.1016/j.ejca.2021.11.032
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Kroese TE] Department of Surgery, Utrecht University Medical Center, Utrecht University, Utrecht, the Netherlands. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. [van Hillegersberg R] Department of Surgery, Utrecht University Medical Center, Utrecht University, Utrecht, the Netherlands. [Schoppmann S] Department of Surgery, Medical University of Vienna, Vienna University, Vienna, Austria. [Deseyne PRAJ] Department of Radiation Oncology, Ghent University Hospital, Ghent, Belgium. [Nafteux P] Department of Surgery, KU Leuven, Leuven University, Leuven, Belgium. [Obermannova R] Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute and Faculty of Medicine, Masaryk University Brno, Brno, Czech Republic. [Alsina M] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid35134666
dc.identifier.wos000792600200002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record